



Contents lists available at ScienceDirect

## Bioorganic &amp; Medicinal Chemistry Letters

journal homepage: [www.elsevier.com/locate/bmcl](http://www.elsevier.com/locate/bmcl)

## Evaluation of analogues of furan-amidines as inhibitors of NQO2

Soraya Alnabulsi<sup>a</sup>, Buthaina Hussein<sup>a</sup>, Elham Santina<sup>a</sup>, Izzeddin Alsalahat<sup>a</sup>, Manikandan Kadirvel<sup>a</sup>, Rachael N. Magwaza<sup>a</sup>, Richard A. Bryce<sup>a</sup>, Carl H. Schwalbe<sup>b,c</sup>, Alex G. Baldwin<sup>a</sup>, Ilaria Russo<sup>d</sup>, Ian J. Stratford<sup>a</sup>, Sally Freeman<sup>a,\*</sup>

<sup>a</sup> Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester M13 9PT, UK<sup>b</sup> School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK<sup>c</sup> Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK<sup>d</sup> School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester M13 9PT, UK

## ARTICLE INFO

## Article history:

Received 23 January 2018

Revised 8 March 2018

Accepted 10 March 2018

Available online xxxx

## Keywords:

NQO2 inhibitors

Furan-amidines

Isosteres

Anti-cancer

Malaria

SAR

## ABSTRACT

Inhibitors of the enzyme NQO2 (NRH: quinone oxidoreductase 2) are of potential use in cancer chemotherapy and malaria. We have previously reported that non-symmetrical furan amidines are potent inhibitors of NQO2 and here novel analogues are evaluated. The furan ring has been changed to other heterocycles (imidazole, *N*-methylimidazole, oxazole, thiophene) and the amidine group has been replaced with imidate, reversed amidine, *N*-arylamide and amidoxime to probe NQO2 activity, improve solubility and decrease basicity of the lead furan amidine. All compounds were fully characterised spectroscopically and the structure of the unexpected product *N*-hydroxy-4-(5-methyl-4-phenylfuran-2-yl)benzamidinium was established by X-ray crystallography. The analogues were evaluated for inhibition of NQO2, which showed lower activity than the lead furan amidine. The observed structure-activity relationship for the furan-amidine series with NQO2 was rationalized by preliminary molecular docking and binding mode analysis. In addition, the oxazole-amidine analogue inhibited the growth of *Plasmodium falciparum* with an IC<sub>50</sub> value of 0.3 μM.

© 2018 Published by Elsevier Ltd.

NRH: quinone oxidoreductase 2 (NQO2) is a cytosolic flavoprotein enzyme<sup>1</sup> widely distributed in human heart, brain, lung, liver and skeletal muscle.<sup>2</sup> NQO2 is a potential target for cancer chemotherapy as its inhibition has therapeutic and/or preventative potential. In our laboratory, non-symmetrical furan-amidine **1** (Fig. 1) and *para*-substituted analogues were identified as novel lead inhibitors of NQO2 with both anti-cancer and anti-malarial activities.<sup>3</sup> Here, further modifications to these non-symmetrical furan-amidines have been evaluated. Some of the non-symmetrical furan-amidines<sup>3</sup> showed poor water solubility, therefore the furan ring of **1** was replaced by more water-soluble isosteric heterocycles, including imidazole and oxazole. The lead NQO2 furan inhibitor possesses the highly basic amidine group, which will potentially decrease its passive diffusion and oral bioavailability.<sup>4,5</sup> Here, analogues of the non-symmetrical furan-amidine **1** were synthesized in which the amidine group was isosterically replaced with less basic groups: imidate, *N*-aryl amidine (reversed amidine), *N*-aryl amide and amidoxime groups. From the initial virtual screening study, one of the first reported potent NQO2 inhibitors


was the symmetrical 3,4-dimethyl-substituted furan-amidine **2** (Fig. 1) with an IC<sub>50</sub> of 50 nM.<sup>6</sup> Given the structural similarity of compounds **1** and **2**, it is of interest to assess the activity of non-symmetrical 4-methylfuran-amidine analogue **3** (Fig. 1) as an NQO2 inhibitor, the synthesis of which is attempted in this study.

In order to enhance the aqueous solubility of furan amidine **1** (clogS −1.81, 4.0 mg/ml<sup>7</sup>), the furan ring was first replaced with an imidazole group to give **4** (clogS −1.27, 13.9 mg/ml<sup>7</sup>). The synthesis of imidazole-amidine **4** is shown in Scheme 1. 4-(4-Phenyl-1*H*-imidazol-2-yl)benzonitrile **7** was synthesized by the reaction of 4-cyanobenzaldehyde **5** with phenylglyoxal monohydrate **6** in the presence of ammonium acetate (Scheme 1).<sup>8</sup> Attempts to convert the nitrile **7** directly into amidine **4** using the Pinner synthesis (Scheme 1, steps iv and v) failed because of the basicity of the nitrogen of the imidazole ring (pK<sub>a</sub> 6.9), causing precipitation of **7** as the hydrochloride salt. Therefore the aryl nitrile **7** was reacted with hydroxylamine to give the amidoxime intermediate **8**,<sup>5</sup> which was reduced to the amidine **4** using ammonium formate<sup>9</sup> (Scheme 1).<sup>10</sup>


The *N*-methylimidazole analogue **9** was synthesized from the reaction of nitrile **7** with methyl iodide (Scheme 2) giving the

\* Corresponding author.


E-mail address: [Sally.Freeman@manchester.ac.uk](mailto:Sally.Freeman@manchester.ac.uk) (S. Freeman).



**Fig. 1.** Structures of the non-symmetrical furan-amidine **1**, the symmetrical 3,4-dimethylfuran-amidine **2** and the proposed 4-methylfuran-amidine **3**.



**Scheme 1.** Synthesis of 4-(4-phenyl-1H-imidazol-2-yl)benzamidinium acetate **4**; Reagents and conditions: (i)  $\text{NH}_4\text{OAc}$ , MeOH, rt. (ii)  $\text{NH}_2\text{OH}\cdot\text{HCl}$ ,  $t\text{-BuOK}$ , dry DMSO,  $0^\circ\text{C}$  – rt; (iii)  $\text{HCO}_2\text{NH}_4$ , Pd/C, AcOH, reflux; (iv)  $\text{HCl}_{(\text{g})}$ , abs. EtOH,  $\text{CHCl}_3$ ,  $0^\circ\text{C}$  – rt; (v)  $\text{NH}_4\text{OAc}$ , Abs. EtOH, rt, 12 h.



**Scheme 2.** Synthetic pathway for 4-(1-methyl-4-phenyl-1H-imidazol-2-yl)benzamidinium acetate **9**; Reagents and conditions: (i)  $\text{CH}_3\text{I}$ , KOH, acetone, rt. (ii)  $\text{NH}_2\text{OH}\cdot\text{HCl}$ ,  $t\text{-BuOK}$ , dry DMSO,  $0^\circ\text{C}$  – rt; (iii)  $\text{HCO}_2\text{NH}_4$ , Pd/C, AcOH, reflux.

possibility of the formation of two regioisomers **10** or **11**. The NOESY spectrum confirmed the formation of the least hindered regioisomer **10** (see Fig. S1) which showed a long-range interaction between the *N*-methyl protons and H-5'. 4-(1-Methyl-4-phenyl-1H-imidazol-2-yl)benzamidinium **9** was synthesized from **10** through the formation of amidoxime **12** (Scheme 2).

The oxazole-amidine **13** (clogS  $-1.30$ ,  $13.3\text{ mg/ml}^7$ ) was synthesized as shown in Scheme 3. The key precursor 4-cyano-*N*-(2-oxo-2-phenylethyl)benzamide **16** was prepared from the coupling between 4-cyanobenzoyl chloride **14** and 2-amino-1-phenylethanol hydrochloride **15**, in the presence of sodium bicarbonate.<sup>11</sup> In the presence of acetic anhydride/conc. sulfuric acid, the benzamide **16** readily cyclised to give 4-(5-phenyloxazol-2-yl)benzonitrile **17**<sup>12,13</sup>, which was converted to the oxazole-amidine **13** through the formation of the amidoxime intermediate **18** (Scheme 3).

The thiophene-amidine **19** (clogS  $-2.25$ ,  $1.57\text{ mg/ml}^9$ ) was also synthesized (Scheme 4) as a more lipophilic isostere of the furan-amidine **1** (clogS  $-1.81$ ,  $4.03\text{ mg/ml}^9$ ). The synthesis of **19** first required the Paal-Knorr synthesis of 2,5-diarylthiophene **21** from

the reaction between the 1,4-diketone **20**<sup>3</sup> and Lawesson's reagent. The conversion of the nitrile group of **21** to the amidine **19** was via the amidoxime intermediate **22**. Reduction of the amidoxime **22** to the amidine **19** was attempted by heating at reflux in acetic acid in the presence of ammonium formate and Pd. Only starting material **22** was recovered, which was attributed to poisoning of the Pd catalyst by the thiophene. The reduction of **22** to amidine **19** was therefore achieved using triethylsilane as hydrogen donor in the presence of palladium (II) chloride catalyst (Scheme 4).<sup>14</sup>

To address the high basicity of the amidine group, several less basic isosteres of **1** were synthesized in which the amidine group was replaced with methyl imidate **23**, amidoxime **24**, *N*-aryl amidines (reversed amidines) **25–26** and *N*-aryl amide **27–29**.  $\text{pK}_a$  and clogS are given in Table 1 and clogP and solubilities (mg/ml) are given in SI for the key compounds, with the non-amidine analogues being less basic, potentially enhancing passive permeability. The syntheses of these analogues are illustrated in Schemes 5 and 6. It was anticipated that heating of ethyl benzimidate hydrochloride **30** (prepared by reaction of nitrile **31** with ethanol)<sup>3</sup> at reflux with ammonium chloride methanol/water would give the furan-amidine **1**, however the isolated product was the methyl imidate **23**<sup>15</sup> (Scheme 5). The methyl imidate group is a much less basic isostere ( $\text{pK}_a$  6.2)<sup>15</sup> than the highly basic amidine group ( $\text{pK}_a$  11.8).<sup>16</sup>

An isosteric analogue of the asymmetric furan-amidine **1** with an amidoxime group **24** was synthesized as a less basic isostere ( $\text{pK}_a$  5–6) for the furan amidine.<sup>17</sup> In addition, the amidoxime group is a known prodrug for the amidine group and can enhance oral bioavailability of amidine-containing drugs<sup>4,5</sup> which is activated through reduction of the amidoxime group by human liver microsomes.<sup>18</sup> *N*-Hydroxy-4-(5-phenylfuran-2-yl)benzamidinium **24** was synthesized by the reaction of nitrile **31** with hydroxylamine (Scheme 5).

The first step in the syntheses of the reverse amidine and amide analogues **25–29** was the preparation of the key 1,4-diketone intermediates **32** and **33**<sup>3</sup> (Scheme 6). The cyclization of the 1,4-diketones **32**, **33** into furans **34**, **35** and thiophenes **36**, **37** were catalysed by dry hydrogen chloride gas and Lawesson's reagent, respectively. The nitro-groups in the intermediates **34–37** were reduced to amines **38–41** using sodium borohydride in the presence of catalytic copper sulfate.<sup>19</sup> The reduction of the nitro-groups into amines was confirmed by upfield shift of the protons on the aromatic ring: The peaks of the H-2', H-4', H-5' and H-6' protons of **34** were shifted up-field from 8.57, 8.12, 7.59 and 8.05 ppm to 6.87, 6.52, 7.08 and 6.94 ppm in **38**, respectively (Fig. S2). The *N*-aryl amidines **25** and **26** were synthesized from the reaction of the amines **39** and **41**, respectively, with *S*-2-naphthylmethyl thioacetimidate hydrobromide (Scheme 6).<sup>20–22</sup> The furan *N*-aryl amides **27** and **28** and *N*-(3-(5-phenylthiophen-2-yl)phenyl)acetamide **29** were synthesized from the reaction of acetyl chloride with amines **38**, **39** and **40**, respectively (Scheme 6).

The synthesis of the 3-methylfuran-amidine analogue **3** was attempted as shown in Scheme 7, however coupling of 4-cyanophenyl methyl ketone **42** and  $\alpha$ -bromomethyl phenyl ketone **43** failed to give the diaryl mono-methyl 1,4-diketone **44**. Diketone **44** would have cyclised to give furan **45**, a precursor for amidine **3**. Instead, the condensation of **42** and **43** led to the formation of

Download English Version:

<https://daneshyari.com/en/article/7779006>

Download Persian Version:

<https://daneshyari.com/article/7779006>

[Daneshyari.com](https://daneshyari.com)